Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.

× No keyword cloud information.

12 in total

1. Using the Internet to conduct surveys of health professionals: a valid alternative?

Authors: Dejana Braithwaite; Jon Emery; Simon De Lusignan; Stephen Sutton
Journal: Fam Pract Date: 2003-10 Impact factor: 2.267

Review 2. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch.

Authors: Sam Schulman; Mark A Crowther
Journal: Blood Date: 2012-02-01 Impact factor: 22.113

3. Which test to use to measure the anticoagulant effect of rivaroxaban: the prothrombin time test.

Authors: A Tripodi
Journal: J Thromb Haemost Date: 2013-04 Impact factor: 5.824

Review 4. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

Authors: Scott Kaatz; Peter A Kouides; David A Garcia; Alex C Spyropolous; Mark Crowther; Jim D Douketis; Anthony K C Chan; Andra James; Stephan Moll; Thomas L Ortel; Elizabeth M Van Cott; Jack Ansell
Journal: Am J Hematol Date: 2012-04-04 Impact factor: 10.047

Review 5. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

Authors: Joanne van Ryn; Joachim Stangier; Sebastian Haertter; Karl-Heinz Liesenfeld; Wolfgang Wienen; Martin Feuring; Andreas Clemens
Journal: Thromb Haemost Date: 2010-03-29 Impact factor: 5.249

Review 6. New anticoagulants: A concise review.

Authors: Lisa M Baumann Kreuziger; Colleen T Morton; David J Dries
Journal: J Trauma Acute Care Surg Date: 2012-10 Impact factor: 3.313

7. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.

Authors: S Schulman; C Kearon
Journal: J Thromb Haemost Date: 2005-04 Impact factor: 5.824

Review 8. Assays for measuring rivaroxaban: their suitability and limitations.

Authors: Edelgard Lindhoff-Last; Meyer Michel Samama; Thomas L Ortel; Jeffrey I Weitz; Theodore E Spiro
Journal: Ther Drug Monit Date: 2010-12 Impact factor: 3.681

Review 9. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.

Authors: Bengt I Eriksson; Daniel J Quinlan; Jeffrey I Weitz
Journal: Clin Pharmacokinet Date: 2009 Impact factor: 6.447

10. Does an offer for a free on-line continuing medical education (CME) activity increase physician survey response rate? A randomized trial.

Authors: Anthony J Viera; Teresa Edwards
Journal: BMC Res Notes Date: 2012-03-07

4 in total

Review 1. Emergency reversal of anticoagulation: novel agents.

Authors: Michael Levine; Joshua N Goldstein
Journal: Curr Neurol Neurosci Rep Date: 2014-08 Impact factor: 5.081

Review 2. Diagnosis and Management of Acute Intracerebral Hemorrhage.

Authors: Andrea Morotti; Joshua N Goldstein
Journal: Emerg Med Clin North Am Date: 2016-09-03 Impact factor: 2.264

3. The Influence of Assay Selection on Prothrombin Time Measured in Patients Treated With Rivaroxaban for Nonvalvular Atrial Fibrillation.

Authors: Daiki Shimomura; Yoshihisa Nakagawa; Hirokazu Kondo; Toshihiro Tamura; Masashi Amano; Soichiro Enomoto; Naoaki Onishi; Yodo Tamaki; Makoto Miyake; Kazuaki Kaitani; Chisato Izumi; Aya Fukuda; Fumihiko Nakamura; Seiji Kawano
Journal: J Clin Lab Anal Date: 2016-04-13 Impact factor: 2.352

Review 4. Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.

Authors: Lisa M Baumann Kreuziger; Joseph C Keenan; Colleen T Morton; David J Dries
Journal: Biomed Res Int Date: 2014-07-20 Impact factor: 3.411

4 in total